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SUMMARY The purpose of this study was to review
the current status of biomarkers used in oro-facial
pain conditions. Specifically, we critically appraise
their relative strengths and weaknesses for
assessing mechanisms associated with the oro-
facial pain conditions and interpret that
information in the light of their current value for
use in diagnosis. In the third section, we explore
biomarkers through the perspective of ontological
realism. We discuss ontological problems of
biomarkers as currently widely conceptualised and
implemented. This leads to recommendations for
research practice aimed to a better understanding
of the potential contribution that biomarkers
might make to oro-facial pain diagnosis and
thereby fulfil our goal for an expanded
multidimensional framework for oro-facial pain
conditions that would include a third axis.
KEYWORDS: chronic oro-facial pain, temporomandib
ular disorders, pain, biomarkers, ontology,
classification
Accepted for publication 31 May 2015
Introduction
The Institute of Medicine (IOM) defines biomarkers as
‘. . . characteristics that are objectively measured and
evaluated as indicators of normal biological processes,
pathogenic processes or responses to an intervention’.
(1) Biomarkers whose relationship to disease is not
clearly established are termed ‘investigative’ (2).
Investigative biomarkers can be developed to differen-
tiate between being diseased and non-diseased (diag-
nostic), to assess the severity or extent of disease
(burden of disease), to predict future onset of disease
(prognostic) and/or to provide information about
treatment effectiveness (efficacy of intervention) (2).
Biomarkers are often used as surrogate endpoints,
that is as a substitute for a clinical endpoint. For
example, in blood pressure trials of antihypertensive
drugs, drug-related decreased blood pressure (the bio-
marker) is associated with the decreased risk of seri-
ous cardiovascular events.
The criteria for evaluation of potential biomarkers
include these three key aspects and their respective
parameters:
1 Analytical validation (sensitivity, specificity, repro-
ducibility, ease of administration)
2 Qualification (evidence for association, study
designs, for example case–control or prospective)
3 Utilisation (specific proposed use)
Blood glucose is a classic example of a biomarker
used to diagnose and monitor diabetes. Glucose is eas-
ily and reliably measured, and well-defined normal
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and pathological ranges for blood glucose exist for the
population. Blood glucose levels are used to monitor
the effectiveness of therapy with insulin and oral
hypoglycaemic agents. The degree to which glucose
concentrations are controlled in diabetic patients can
be used to predict long-term consequences of disease
progression.
The authors of this study were invited by the
International RDC/TMD Consortium Network for a
symposium, held at the 2013 IADR General Session
in Seattle, in order to review biomarkers related to
the development of an oro-facial pain classification
system. The other two studies are focused on gen-
eral principles of ontology (3) and psychosocial con-
siderations related to an oro-facial pain taxonomy
(4). This study will first discuss biomarkers, in the
context of usage in an oro-facial pain diagnostic and
classification system, and then, it will critically
assess the various problems that affect such poten-
tial usage.
Biomarker candidates for oro-facial pain
Biomarkers for oro-facial pain discussed in this study
can be categorised by the method used to measure
them: (i) physiological (e.g. reflex responses, pressure
pain thresholds, quantitative sensory testing); (ii) psy-
chological or behavioural characteristics (e.g. dynamic
pain psychophysical testing); (iii) radiological [com-
puted tomography (CT), magnetic resonance imaging
(MRI), functional MRI (fMRI), positron emission
tomography (PET)]; and (iv) molecular [small mole-
cules (amino acids, prostaglandins, leukotrienes) and
proteins (e.g. cytokines, COX, etc.)]. Increasingly
investigated biomarkers are genomic and transcrip-
tomic in nature, but this is beyond the scope of this
study. The following sections discuss the use and
potential application of some of these biomarker can-
didates and applicable tests.
We have grouped potential craniofacial biomarkers
into three categories, based on their method of acqui-
sition as follows: direct physiological measures, bios-
amples and imaging (5). Direct physiological
measures require the use of a stimulus that is typi-
cally nociceptive (e.g. pressure, thermal) but it may
also be non-nociceptive (e.g. pressure, movement),
and such measures assess the impact of the stimulus
on a physiological (reflex) or behavioural response as
the measurement. Molecules (metabolites, proteins,
nucleic acids, etc.) are assessed via a biosample (e.g.
blood, saliva, cerebrospinal fluid, tissue biopsy), and
the process of acquiring a sample may include a stim-
ulus (for example, nociceptive) or sample acquisition
may be with the organism at rest, and while a
behavioural response by the individual may accom-
pany the process of collecting the sample, such a
response is not necessary nor is the response part of
the measurement. Imaging includes magnetic reso-
nance imaging (MRI)-based techniques (diffusion ten-
sor imaging, spectroscopy, volumetric MRI, functional
MRI), X-rays including computed tomography scans,
positron emission tomography, which reveal struc-
tural changes and can also provide information about
local metabolic activity.
Direct physiological measures
Pressure pain threshold (PPT) is the minimum load
required to cause a painful sensation from a specific
tissue (e.g. skin, muscle, joint) and forms part of the
compliment of tests employed in quantitative sensory
testing (QST; discussed below). Pressure pain threshold
can be easily measured in an office with an algometer.
Pressure pain threshold can be used for diagnosis and
to determine treatment efficacy, for example, by
assessing pain sensitivity in the masticatory muscles
and the temporomandibular joint of individuals with
symptoms compatible with temporomandibular disor-
ders (TMD). It has been suggested that PPT in the mas-
seter muscle may be as good as palpation to recognise
TMD-related pain (6). One advantage of PPT measure-
ment data is that they are usually found to have good
to excellent interexaminer reliability (7). However, to
use PPTs in this way would require that there be stan-
dardised, accepted instrumentation for measuring
them, standardised units for reporting the load, specific
criteria for PPT application (loading area, rate of stimu-
lus application, sites to be tested, number of trials) and
perhaps a determination of what other factors might
significantly affect the PPT (menstrual cycles, diurnal
cycle). Also to be determined are what constitute
normal values in healthy individuals, and what values
fall outside of the range of ‘normality’ (8). Although
substantially lower masticatory muscle PPT values
have been found in large cohorts of TMD patients
when compared with healthy controls (7), these differ-
ences have not always been detected in small
group studies due to the variability inherent in PPT
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values (9, 10), reducing the diagnostic utility of this bi-
omarker. It is unclear whether analgesic interventions
alter both PPT and TMD symptoms in a related man-
ner, and this question warrants further investigation.
The jaw-stretch reflex is a monosynaptic stretch
reflex that can be evoked by rapid depression of the
mandible. Jaw-stretch reflexes can be measured in an
office, but accurate measurement requires relatively
complex equipment. Because some factors (e.g. EMG
activity and jaw displacement) influence the amplitude
of the reflex itself, while other factors (e.g. recording
site) influence the amplitude of the registered mea-
surement, standardised parameters for measuring jaw-
stretch reflexes would need to be developed. While it
is clear that experimental muscle pain alters the ampli-
tude of the stretch reflex (11–14), it is not clear
whether clinical pain, such as masticatory muscle pain
associated with TMD, reliably modulates this reflex. In
TMD patients with joint pain, injection of lidocaine
into the joint reduces the jaw-stretch reflex and ongo-
ing pain (15). On the other hand, skeletal muscle
relaxants have very little effect on enhancement of the
reflex that can be produced by experimental masseter
muscle pain (16). Thus, the jaw-stretch reflex may be
more useful in assessing the integrity of the trigeminal
sensory system, rather than as a biomarker of disease
for TMD (15, 17–19).
Traditional quantitative sensory testing (QST) pro-
vides a powerful method of assessment for sensory
functioning and for the effectiveness of different treat-
ments (20). In this method, standardised non-invasive
stimuli of different modalities are applied to measure
the functionality of different nerve fibre populations.
As an indication of response, the method relies on
subjective verbal or non-verbal report (20), and the
assessment of functioning is made through evaluation
of sensory thresholds (detection and pain thresholds,
pain tolerance, pain summation thresholds), supra-
threshold intensity ratings (response–magnitude and
stimulus–response relationships) and sensory mapping
(20). The assumption is that the responses to various
stimuli provide information about the functionality of
the peripheral and central nervous systems.
Standardisation is difficult to achieve with QST, as
data from one assessment system cannot be easily
compared to another. This discrepancy can be some-
what reduced by routinely using the same methods
and devices, and using the patient’s contralateral side
as a reference when possible (21). To maximise accu-
racy, QST analysis should assess sensitivity at a num-
ber of locations: the painful (affected area),
contralateral and neighbouring sites, and non-related
sites. All tested locations should be methodically
mapped and sensory alterations beyond the primary
affected site may indicate systemic disease or centrally
mediated conditions that will require further evalua-
tion. A major limitation to standardisation that is
more difficult to overcome is that the test’s accuracy
relies on patient responses. The patient’s response can
be biased, influenced either by a time gap between
experiencing the sensation and providing the
response, or by a range of expectations specific to the
patient. These biases can generally be controlled by
more sophisticated but time-consuming psychophysi-
cal methods (staircase, etc.).
Quantitative sensory testing alone has no diagnos-
tic power; however, it can add an additional dimen-
sion to pain evaluation. Various clinical conditions
and pathological processes may have a different,
characteristic sensory signature. For example, severe
nerve injury (partial or complete nerve transection)
is typically characterised by immediate myelinated
and unmyelinated nerve fibre hyposensitivity that
will be represented by elevated detection thresholds
of sensitivity to all modalities (22). Partial damage
may be followed by either hyposensitivity or hyper-
sensitivity accompanied by ongoing neuropathic pain
(23, 24). Another example is that early perineural
inflammation may produce short-lasting large mye-
linated nerve fibre hypersensitivity that is revealed
clinically by reduced detection threshold in those
fibres (25–30).
Employing QST can enable the practitioner to dis-
tinguish between allodynic conditions (i.e. where pain
is caused due to a stimulus that normally would not
evoke pain). In allodynia conditions, the pain thresh-
old is reduced whereas the detection threshold can
increase, decrease or remain unchanged. The interval
between detection and pain thresholds, for example,
has been shown to have clinical significance in the
assessment of centrally mediated pain conditions (31).
Similarly, several types of hyperalgesic conditions can
be defined as well. Heat hyperalgesia, for example, is
related to thin unmyelinated nerve fibres, while tac-
tile hyperalgesia may suggest involvement of myelin-
ated fibres.
A significant attempt to standardise QST was made
by The German Research Network on Neuropathic
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Pain (32). The Network employed a systematic
sequence of thermal and mechanical QST on patients
suffering from various neuropathic pain conditions.
The findings were categorised as gain and loss of
sensation. Ninety-two per cent of the patients pre-
sented with at least one sensory abnormality, and a
sensory profile was suggested for each neurological
syndrome. However, combinations of gain and loss
of sensations were found to exist across all the eval-
uated pain syndromes, thereby reducing diagnostic
specificity. Nevertheless, there is preliminary evi-
dence for alterations in the QST profiles of some
patients with TMD compared to healthy controls and
chronic widespread (fibromyalgia) patients (33), sug-
gesting that QST may be able to provide specific
pain signatures that could be used to assist in the
diagnosis of oro-facial pain conditions. However, as
mentioned earlier, this method alone has no diag-
nostic power. Guidelines for the assessment of oro-
facial somatosensory function in the clinical setting
exist (20), but they are not yet standardised or vali-
dated; consequently, there is an ongoing effort to
develop consistent approaches for assessment (34).
These will be required for this technique to be eval-
uated as a potential biomarker of TMD and other
oro-facial pain conditions.
Dynamic pain psychophysical testing is part of a
new generation of psychophysical testing that allows
for the evaluation of modulatory processes. This
method comes in addition to recognising the pain per-
ception obtained by static pain psychophysics of
thresholds or supra-threshold magnitude evaluation,
described above under QST. The technique relies on
the fact that pain perception is the result of generated
data from the periphery, which is transmitted cen-
trally, and then modulated in the CNS before its arri-
val in the cortex for conscious perception. Therefore,
the same type of external stimulus may evoke percep-
tions of different sorts among different people,
depending on their central modulation processes and
the situation they are in.
Two modulatory mechanisms are commonly tested
in the laboratory or clinic. One is temporal summa-
tion (TS), the psychophysical correlate of ‘wind-up’,
a process whereby repeated noxious stimulation
results in progressively larger neuronal responses
and reflects central sensitisation; note that TS is
often subsumed within the QST rubric. Temporal
summation is thought to result from increased acti-
vation of N-methyl-D-aspartate (NMDA) receptors in
response to sustained nociceptive input. The clinical
manifestation of TS may be allodynia and hyperal-
gesia (35–37). TS is tested by application of a num-
ber of repeated nociceptive stimuli at a fixed
interval. The increase in pain score is assessed at
the end of the final stimulus. The second mecha-
nism is conditioned pain modulation (CPM), which
is thought to be the human psychophysical equiva-
lent of diffuse noxious inhibitory control (DNIC).
Conditioned pain modulation represents the endoge-
nous analgesia system, where descending pathways
induce modulatory effects on incoming painful stim-
uli. This phenomenon, at least partially, is opioid-
mediated (38). Animal studies demonstrated the role
of spinal noradrenaline (NA) and serotonin (5-HT)
in mediation of pain inhibition and CPM (39–44).
Conditioned pain modulation is tested in the labora-
tory using two remote noxious stimuli, where the
first ‘conditioning pain’ inhibits the second ‘test
pain’.
In recent years, many reports used TS or CPM to
demonstrate altered pain modulation in chronic pain
patients. Enhanced TS was found in chronic pain
patients such as fibromyalgia (45–48), tension head-
ache and musculoskeletal pain (49, 50), migraine
(51), chronic low back pain (52), and temporoman-
dibular disorders (TMD) (53–57). Similarly, a less-effi-
cient CPM response was found in many of the
idiopathic pain syndromes such as TMD (58), fibrom-
yalgia (48, 59–61), tension headache (62) and irritable
bowel syndrome (63). Among healthy subjects,
reduced pain modulatory capacity was demonstrated
in older subjects (64) and among females when com-
pared with males (65). Less-efficient CPM was found
among patients with chronic post-endodontic treat-
ment pain as well (C. Nasri-Heir, J. Khan, B. Benoliel,
C. Feng, D. Yarnitsky, F. Kuo, C. Hirschberg, G. Hart-
well, C.-Y. Huang, G. Heir, O. Korczeniewska, S.R.
Diehl & E. Eliav, unpublished data).
It has been suggested that dysregulation of the pain
modulatory system can lead to the development of
chronic pain disorders (66–69). Patients with altered
pain modulation are more prone to develop post-
operative (thoracotomy) chronic pain (70). Moreover,
a recent study has shown that painful diabetic neu-
ropathy patients with less-efficient CPM benefit more
from treatment with duloxetine (71) that has the
potential to enhance the descending pain inhibition
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by inhibiting reuptake of spinal noradrenalin (NA)
and serotonin (71–73).
The pain modulatory system can be activated by
stimuli other than pain; isometric contraction and exer-
cise have been shown to be strong descending pain
inhibitory system motivators (74). A recent study
demonstrated that subjects with high CPM induced by
painful heat stimulus also exhibited high CPM induced
by isometric contraction (D.A. Alnaas, C. Nasri-Heir &
E. Eliav, unpublished data). This may suggest common
mechanisms or pathways for pain-induced and isomet-
ric muscle contraction-induced CPM.
Biosamples
Biomarkers from blood have been identified for many
diseases, including the example of diabetes given ear-
lier. There are reasonably good biomarkers of inflam-
mation, but as yet it has been difficult to find a
molecular biomarker of pain, let alone for a specific
type of pain such as oro-facial pain related to TMD.
This is compounded by the finding of little evidence
of gross pathological changes to the masticatory mus-
cle tissues of TMD patients with myalgia (75). Despite
the lack of gross pathology, microdialysis studies have
recently found that interstitial glutamate concentra-
tions are 2–4 times greater in the masseter muscle of
myofascial patients with TMD than in healthy con-
trols (9). In an animal model, a similar 2–3 times ele-
vation of interstitial glutamate concentrations over
baseline in the masseter muscle is associated with
excitation and mechanical sensitisation of masseter
muscle nociceptors (76). These findings could indicate
that glutamate concentration in the masseter muscle
reflects ongoing disease and therefore could serve as a
diagnostic biomarker. In addition to glutamate, studies
employing microdialysis have demonstrated elevated
levels of serotonin, leukotriene B4, lactate and pyru-
vate in localised myalgias; however, most of these
results have come from studies on muscles other than
masticatory muscle in patients who had chronic myo-
fascial pain that was not diagnosed as a TMD (77).
Other molecular biomarkers of disease have been
identified in the TMJ, including tumour necrosis factor
(TNF)a, an inflammatory cytokine which is found at
significantly higher concentrations in the TMJ synovial
fluid of patients with evidence of joint damage (78,
79), although there is no correlation between pain and
TNFa concentrations (80). Recently, blood levels of
three other cytokines, monocyte chemotactic protein-1
(MCP-1), interleukin (IL) 1ra and IL-8, have been
shown to be expressed at higher levels in patients with
TMD compared to healthy controls, and their pattern
of expression appears to differentiate patients with
widespread pain from those with pain localised to the
oro-facial region (81). Specifically, MCP-1 and IL-1ra
are selectively elevated in TMD patients with localised
pain, while IL-8 is selectively elevated in TMD patients
with widespread pain. Monocyte chemotactic protein-
1 is a pro-inflammatory cytokine released upon local
inflammation and promotes the release of CGRP. IL1ra
is anti-inflammatory and blocks IL1 pathway mediat-
ing pain. IL-8 is pro-inflammatory and may also be ele-
vated in fibromyalgia.
Imaging
Imaging techniques that have been employed to
investigate central nervous system function in oro-
facial pain research include computed tomography
scans, magnetic resonance imaging (MRI), functional
MRI (fMRI) and positron emission tomography (PET)
scans (82–85). Other magnetic resonance-based mea-
sures include diffusion tensor imaging, spectroscopy
and volumetric imaging (86). In terms of central ner-
vous system function, fMRI has been employed to
identify cortical and subcortical regions that appear to
be activated during painful experiences, although
none of the structures activated are uniquely acti-
vated by pain (86). Thus, while no specific pattern of
brain activation has yet been identified in individuals
suffering from pain, several lines of evidence suggest
that the insular cortex may be a critical site of pain
integration (86). There is some evidence that cortical
activation induced by innocuous stimulation differs
under conditions of ongoing oro-facial pain. Through
the use of fMRI, it has been found that experimental
pain from the facial skin or masseter muscles causes
bilateral activation of the ventroposterior thalamus
(VPM), whereas innocuous stimulation (brushing the
face) results only in the activation of the contralateral
VPM. This suggests that fMRI signals from the thala-
mus may prove useful as a means to differentiate
between noxious and innocuous pain input from the
face (84). Cortical activation in response to low fre-
quency vibration of the index finger in patients with
TMD appeared to be increased in several key regions
when compared to healthy controls, but no major dif-
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ference in the pattern of activation was identified
(83). At present, fMRI patterns cannot be used as a
biological marker of oro-facial pain.
For imaging of masticatory muscles or TMJ, there
are comparatively fewer options (87–89). One very
interesting technique that has been recently applied
to study patients with TMD is MRI diffusion tensor
imaging/fractional anisotropy to assess white matter
in the central roots of the trigeminal nerve (90). This
technique employed fractional anisotropy, a measure
of relative diffusion in three dimensions. It is thought
that decreases in fractional anisotropy reflect nerve
pathology such as decreased fibre density, axonal
diameter or myelination. Patients with TMD had sig-
nificantly lower levels of fractional anisotropy in the
central root of the trigeminal nerve, which may indi-
cate that this technique has identified a pathological
change in the trigeminal nerve associated with TMD-
related pain. The degree of fractional anisotropy is
associated with disease duration, making this potential
biomarker a candidate for both diagnosis and disease
burden, if these findings can be replicated in larger
patient cohorts. Unfortunately, MRI is expensive and
the availability of MRI machines varies greatly in dif-
ferent countries (78, 88, 91).
Ontological perspectives on biomarkers
and diagnostic classifications for oro-
facial pain disorders
The standard definition for ‘biomarker’ violates ontological
principles
For the notion of a biomarker to play a prominent
role in diagnostic classifications, for instance in the
formulation of diagnostic criteria, there must be a
uniform understanding among developers of such
classifications about what biomarkers precisely are
and whether all entities to which the term ‘biomar-
ker’ is assigned form a uniform group. For a group of
entities to be uniform, all and only its members must
exhibit a certain combination of characteristics and
this is so irrespective of whether science has advanced
enough to discover this unique combination of char-
acteristics and whether an appropriate terminology
has been developed to report on these characteristics
adequately. This understanding must thus also include
in what way biomarkers are distinct from other enti-
ties on the side of the patient such as signs, symptoms
and diagnostic tests that are applied to them – all enti-
ties which are already standardly referred to in the
formulation of diagnostic classes and corresponding
criteria. And finally, a similar understanding must be
established for each of the various sorts of biomarkers
as, for instance, suggested by terms used in previous
sections such as ‘investigative biomarkers’, ‘prognostic
biomarkers’, ‘radiologic biomarkers’ and so forth.
Unfortunately, the IOM has not provided a defini-
tion for ‘biomarker’ which is such as to denote all and
only entities from some uniform group. The definition
exhibits, for example, the conflation often encoun-
tered in medical discourse between entities on the side
of the organism – in the case of health care: human
beings – and the evidence for the existence of such enti-
ties (92). This and other conflations are widespread,
and it is thus no surprise to find examples thereof in
the IOM’s report on biomarkers, for instance in ‘Cho-
lesterol and blood sugar levels are biomarkers, as are blood
pressure, enzyme levels, measurements of tumour size from
MRI or CT, and the biochemical and genetic variations
observed in age-related macular degeneration.’ (1)[p2]
where characteristics on the side of the patient are
conflated with measurements of these characteristics.
Moreover, it is even unclear whether by ‘measure-
ments’ is meant either (a) the processes of measuring
an entity on the side of the patient or (b) the data –
usually expressed as values of some sort – obtained
through such a process of measuring. In (1)[p18], the
need is expressed ‘. . .to develop a transparent process for
creating well-defined consensus standards and guidelines for
biomarker development, validation, qualification, and use
[bold emphasis added] to reduce the uncertainty in the
process of development and adoption.’ This would restrict
biomarkers to be measuring processes and/or devices
to assist in such processes as it is hard to fathom that
what is proposed to be developed here are blood sugar
levels and tumour sizes. But that then, in turn, cannot
be lined up with the IOM’s definition for biomarker
which is stated to be something that is (i) objectively
measured – surely, the idea is not that what is mea-
sured would be the measuring process of, for instance,
blood glucose itself – and (ii) an indicator for normal,
pathological or response to treatment processes –
clearly, the mere performance of some test is itself not
an indication at all of what is going on in the patient,
rather an indication of what is going on in the mind
of the clinician as he is trying to find out what is going
on in the patient.
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That the terminology around biomarkers is incon-
sistent – a problem the IOM recognises in its own
report (1)[p22] but unfortunately is contributing to
rather than solving it – does not mean that the ideas
behind it do not have value. But it does mean that
the terminology needs to be rendered unambiguous
and anchored in an ontology which recognises all
types of entities to be referred to in standards and
guidelines for biomarker development, validation,
qualification and use.
Biomarkers under the perspective of the Ontology of General
Medical Science (OGMS)
Ceusters and Smith have recently proposed an onto-
logical realism-based account for biomarkers (93).
This account renders IOM’s view of biomarkers coher-
ent under the following assumptions: (i) that the IOM
intended biomarkers to be entities on the side of the
patient, and not (for example) processes on the part
of the clinician or data obtained through such pro-
cesses including what can be seen or measured, for
example in radiographic images; (ii) that in requiring
that biomarkers be ‘objectively measured and evalu-
ated’ the IOM had in mind not that an entity
becomes a biomarker after and because it has been
measured and evaluated, but rather that it was a bio-
marker already prior to observation because of certain
properties it has intrinsically; and (iii) that the logical
disjunction expressed by the ‘or’ in the list of pro-
cesses for which the IOM definition asserts biomarkers
to be an indicator has to be interpreted as an exclu-
sive or (XOR). Thus, they assume that the IOM would
not accept as biomarker some entity ‘e’ from which it
cannot be determined whether ‘e’ is the result of a
normal process or of a pathological process, and so
forth. Under these assumptions, it is possible to inter-
pret the vague term ‘characteristic’ in the IOM defini-
tion as denoting that what is intended by the OGMS
term ‘bodily feature’ (92).
Entities that qualify as bodily features are instances
of one or other of the following three disjoint types:
(i) physical bodily components (nerve cells, nocicep-
tors, neurotransmitters, etc.) and components in the
interior or on the surface of the body (pathogens, tox-
ins, microbiome, . . .); (ii) bodily qualities such as
cytokine concentrations; and (iii) bodily processes in
which physical components participate, irrespective of
them being normal (e.g. neurotransmission and con-
cordant pain sensation), pathological (e.g. phantom
pain) or induced through interventions.
Conclusion
Uses of biomarkers for oro-facial pain
Biomarkers are needed to serve as diagnostic, burden
of disease, prognostic or efficacy of intervention tools
for temporomandibular disorders and other oro-facial
disorders causing pain. At present, however, there are
no validated biomarkers of oro-facial pain. An ideal bi-
omarker needs to be easily and reliably measured
either by a trained clinician in the office or by a labo-
ratory. Methodologies that provide or could provide
fingerprint or signature type information, such as
genetic or molecular profiling, QST- or MRI-based
techniques or combinations of various techniques may
define the unique pathology associated with oro-facial
conditions. However, these techniques are, at the
moment, still time-consuming, complicated and
expensive, and consequently, their value as biomar-
kers will require the development of standardised and
feasible clinical protocols as well as strong evidence for
their diagnostic utility before they will be accepted into
the mainstream of clinical assessment of oro-facial
pain. Given these constraints, there is a need to con-
tinue to evaluate the simple biomarkers of oro-facial
pain such as physiological and molecular biomarkers.
Recommendations for ontology-based representation of
biomarkers in diagnostic classifications and related criteria
for oro-facial pain
Both researches aiming at the discovery of suitable bi-
omarkers for oro-facial pain and the adequate use
thereof to build diagnostic classifications will benefit
from the advantages ontology has to offer. An initial
goal will be to clean up the terminology around bio-
markers, the scope of which is much broader than
only the domain of pain research. If this is not imme-
diately feasible for biomedicine in general, then at
least pain researchers could get a competitive advan-
tage by implementing a few simple steps.
A good start would be to develop on the basis of
the literature an inventory of biomarker candidates
relevant for pain research and subsequent application
for diagnostics. This inventory should include, for
each biomarker, a number of essential information
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elements. One element is the type of bodily feature
the biomarker is an instance of; the most generic and
minimum allowed types, in terms of the OGMS, are
physical component, bodily process, and bodily qual-
ity. If the biomarker is determined to be a physical
component, then further subtyping should be docu-
mented using ontologies accepted in the Open Bio-
medical Ontologies Foundry (94) or candidate
ontologies thereof; examples are the Foundational
Model of Anatomy (95) for any bodily component
down to individual cells, the Cellular Component tax-
onomy of the Gene Ontology (96), the Protein Ontol-
ogy (97) and so forth.
If the biomarker is a bodily process, good candidate
ontologies for clarifying the terminologies are the Bio-
logical Process and Molecular Function taxonomies of
the Gene Ontology. As bodily processes always
depend on at least one bodily component, it should
for such a biomarker also be indicated which bodily
components it depends on, using one of the ontolo-
gies just mentioned. If that is not documented in the
ontology used to type the biomarker, it should be
added to the inventory of biomarker candidates.
If the biomarker is a bodily quality, a good ontology
for further subtyping is the Phenotypic Quality Ontol-
ogy (PATO) (98). As with processes, the biomarker
candidate inventory should further contain informa-
tion about what bodily component this biomarker is a
quality of.
The second sort of information the inventory
should contain is the type of investigation used in the
cited literature source to determine the biomarker
being documented. A candidate ontology for this is
the Ontology of Biomedical Investigations (OBI) (99).
As various types of assays can be used to measure the
same biomarker, each biomarker might need several
distinct measurement-related entries.
The third piece of information is, in case of an
inventory aimed towards diagnostic classification
development, where the biomarker is believed to be
an indicator of the underlying pathology. This infor-
mation is typically available as a diagnosis.
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